Kwality Pharmaceuticals: ICRA Boosts Credit Rating, Raises Bank Limits to ₹200 Crore

Consolidated revenue for the first nine months of FY2026 reached ₹346.0 crore, with an operating profit margin of 23.0% during the same period.

What Happened

ICRA has upgraded the credit ratings for Kwality Pharmaceuticals Limited (KPL), signaling a significant improvement in its financial standing.
The long-term rating is now [ICRA]BBB+ (Stable), and the short-term rating is [ICRA]A2.
Notably, the total rated bank facilities have been increased substantially to ₹200.00 crore, up from ₹65.00 crore.
Kwality Pharmaceuticals has also been removed from ICRA's 'Issuer Not Cooperating' category, indicating enhanced transparency and engagement.

Why It Matters

This upgrade highlights Kwality Pharmaceuticals' stronger creditworthiness and better financial management.
Increased access to rated credit facilities can lead to more favorable borrowing terms and greater financial flexibility for expansion.
Its removal from the 'Issuer Not Cooperating' status is a positive sign for corporate governance and investor confidence.

Background

Kwality Pharmaceuticals previously faced rating downgrades and was placed in ICRA's 'Issuer Not Cooperating' category due to a lack of timely financial information for rating surveillance.
The current upgrade shows the company has resolved these issues, providing ICRA with sufficient data to reassess its financial health.
The significant jump in rated bank facilities from ₹65 crore to ₹200 crore reflects a strong renewal of lender confidence.

What This Means Now

• Improved access to debt financing at potentially better interest rates.
• Enhanced financial stability and a stronger perceived balance sheet.
• A better relationship with lenders and regulatory bodies.
• Greater capacity to fund planned capital expenditures and business growth.

Risks to Monitor

• High working capital needs, as shown by an NWC/OI of 50.2% in FY2025, due to extended customer payment terms and inventory buildup.
• Success in launching and scaling complex products like peptides and biosimilars is crucial for ongoing revenue growth.
• Profitability can be affected by raw material price swings and currency volatility, given import reliance and substantial exports.
• Exposure to evolving regulations, including pricing controls and facility approvals in various international markets.
• Intense market competition could limit pricing power.
• Future ratings might face pressure if debt-financed capital spending exceeds projections or if working capital cycles lengthen further.

Peer Comparison

Kwality Pharmaceuticals competes in a busy market with companies like Indoco Remedies. While Indoco Remedies, a similarly sized mid-cap firm, also produces formulations and APIs for domestic and export markets, Kwality Pharma is increasingly focusing on complex products such as peptides and biosimilars for its future growth.

Key Figures

• Consolidated revenue for the first nine months of FY2026: ₹346.0 crore.
• Consolidated operating profit margin for the first nine months of FY2026: 23.0%.
• Total debt as of September 30, 2025: ₹110.4 crore.
• Interest coverage ratio in the first half of FY2026: 8.8 times.
• Working capital intensity (NWC/OI) in FY2025: 50.2%.

What to Track Next

• Progress on planned capital expenditures: ₹70 crore in FY2027 and ₹40 crore in FY2028.
• The company's success in launching and expanding sales of complex products, especially in oncology.
• How the company manages its working capital intensity and its financial impact.
• Any new rating rationales or updates from ICRA.